drugset
drugset / Trial / NCT01402271

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

NCT01402271 ↗

Phase 1/2 Completed 88 enrolled European Organisation for Research and Treatment of Cancer - EORTC
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of pazopanib hydrochloride when given together with paclitaxel and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.

Timeline

Start
2012-07
Primary completion
2019-05-15
Completion
2020-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 2 unknown Intravenous
Subject Carboplatin Small molecule 2.7 unknown Intravenous
Subject Paclitaxel Small molecule 30 mg/m2 Intravenous
Subject Paclitaxel Small molecule 60 mg/m2 Intravenous
Subject Pazopanib Small molecule 400 mg Oral

Indications

fallopian tube cancer ovarian carcinoma primary peritoneal carcinoma